Federal Cannabis Legalization Bill Returns to the Senate, What Patients and Clinicians Should Watch
The 2026 cannabis federal legalization bill reintroduced in the Senate signals major policy shifts. Patients and clinicians should understand its potential impact and current limitations. This bill outlines federal descheduling and regulatory frameworks…
Congressional Options to Rewrite Marijuana Gun Ban After Hemani
The congressional marijuana gun ban rewrite remains an open option after the Hemani ruling. Congress still has room to change federal marijuana gun law. Patients and clinicians should understand the evolving marijuana firearm ownership federal policy.
The DEA’s New Cannabis Registration System May Matter More Than Legalization Headlines
The DEA’s new cannabis registration system may quietly reshape American cannabinoid medicine. This policy shift could influence research, taxation, institutional acceptance, and physician participation far beyond the headlines. Here is what clinicians…
What the New Gun Purchase Form Means for Cannabis Patients
ATF Form 4473 medical cannabis language may be changing after the 2026 Schedule III rescheduling order. The proposed revision removes the old warning that treated medical marijuana the same as recreational or unlawful use. This article explains what…
What the 2026 DOJ Rescheduling Order Means in Practice
On April 23, 2026, the U.S. DOJ moved state-licensed medical cannabis to Schedule III, the first federal acknowledgment of accepted medical value in 55 years. Dr. Caplan breaks down what actually changed for patients, physicians, and the research…
regulations.gov
A docket-related update affecting cannabinoid labeling, compliance posture, and agency comment review.
AM Policy Update: March 15, 2026
The DEA scheduling cannabis policy update on March 15, 2026, highlights key regulatory changes affecting cannabis medicine. This includes temporary placements and rescheduling of substances relevant to controlled substances regulations. Understanding…